Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P14784
UPID:
IL2RB_HUMAN
Alternative names:
High affinity IL-2 receptor subunit beta; Interleukin-15 receptor subunit beta; p70-75
Alternative UPACC:
P14784; B2R765
Background:
The Interleukin-2 receptor subunit beta, also known as High affinity IL-2 receptor subunit beta and Interleukin-15 receptor subunit beta, plays a pivotal role in the immune system. It is crucial for the receptor-mediated endocytosis and mitogenic signals transduction of IL2, and, in association with IL15RA, enhances neutrophil phagocytosis stimulated by IL15.
Therapeutic significance:
Linked to Immunodeficiency 63 with lymphoproliferation and autoimmunity, this protein's understanding could pave the way for innovative treatments targeting immune dysregulation and enhancing viral infection defenses.